Two treatment approaches for advanced throat cancer: comparing timing of immunotherapy

Plain-English translation of NCT07706985 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial compares two ways of combining chemotherapy, immunotherapy, and radiation therapy for people with locally advanced nasopharyngeal cancer (a type of throat cancer). One approach gives toripalimab and throughout all phases of treatment, while the other approach gives toripalimab only before and after radiation therapy, with given during radiation. The goal is to see if the second approach works just as well while being easier on the body.

Doctors know that adding immunotherapy drugs to standard treatment helps people with this type of cancer live longer, but giving these medications throughout the entire course of radiation therapy can weaken the immune system and cause severe side effects. This trial is testing whether giving the medication in a more targeted way—skipping it during the radiation phase—can keep the survival benefits while reducing harmful side effects.

Do you qualify?

You likely qualify if…

you are between 18 and 70 years old
you have been diagnosed with advanced nasopharyngeal cancer (stage III or IV-A, with specific limitations)
you are in good enough health to handle treatment, with normal or near-normal blood counts, liver, and kidney function
you have not had another cancer diagnosis in the past 5 years
you are willing to provide written consent and attend all study visits

You likely don't qualify if…

you have had another cancer in the past 5 years (except certain skin cancers)
you have active or poorly controlled hepatitis B or hepatitis C, or HIV infection
you have a history of serious lung disease or pulmonary fibrosis
you have severe heart failure or significantly weakened heart function
you have active tuberculosis or were recently treated for tuberculosis

What participation looks like

You would receive chemotherapy first, combined with two immunotherapy medications and possibly more of the same medications depending on which group you are randomly assigned to. Then you would receive radiation therapy to the tumor site, with one group continuing both immunotherapy medications during radiation and the other group receiving only one of them. After radiation, you would continue with follow-up immunotherapy medication. The full treatment typically lasts several months, and you would need to attend regular clinic visits for blood tests, scans, and physical exams to monitor how well the treatment is working and manage any side effects.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Two treatment approaches for advanced throat cancer: comparing timing of immunotherapy

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)